Prescription Biosimilars

Thursday, January 23, 2025, 11:30 AM - 1:00 PM

Fee: Free (UC Learner Only)*

Registration Instruction

1. Click "Register" tab on the course page or follow the direct link here: Click Here

2. Sign-in to CloudCME or create new account. If you are affiliated with UCLA, please use Single Sign On (SSO) log-in option.

3. Select the registration type "Prescription Biosimilar - UC Learner Only Registration (Free) - $0.00".

4. Click blue "Continue" button at the bottom of registration page. You do not need to insert or submit any code as there will be no cost to this registration.

5. Complete the short registration survey and click blue "Continue" button at the bottom of the page.

6. Your registration is complete, and you will receive the receipt on your email. The registration and receipts are also available in "Registrations and Receipts" section in CloudCME under My CME (direct link: https://ucla.cloud-cme.com/cme/receipts?P=800).

*This course is exclusively for UC learners. During registration, you will be asked to provide your UC-affiliated email address for verification. Registrations submitted without this information or those that fail validation will be automatically canceled and notified via email.

* Approved registrations will receive their zoom links via email 2-weeks before the course date.

Cancellation Policy
All cancellations must be submitted in writing via email to  [email protected] to ensure accurate tracking of registrants.

Course Recording
The course recording will be made available as an enduring material course after the course.

1. Identify the range of FDA-approved prescription biosimilars available for treating chronic conditions.
2. Explain the regulatory approval process and clinical evidence supporting prescription biosimilars efficacy and safety.
3. Demonstrate the ability to integrate prescription biosimilars into patient treatment plans, considering individual patient needs and preferences.
4. Assess the impact of prescription biosimilar adoption on healthcare costs and patient outcomes, with a focus on the California patient population.
5. Develop strategies to address operational and clinical barriers to prescription biosimilar adoption within healthcare settings.
6. Critically evaluate the effectiveness of implemented strategies in improving prescription biosimilar utilization and reducing health disparities.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of David Geffen School of Medicine at UCLA and University of California Office of the President. The David Geffen School of Medicine at UCLA is accredited by the ACCME to provide continuing medical education for physicians.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

AMA PRA Category 1 Credits™ (3.00 hours), ABIM MOC Part 2 (3.00 hours), Non-Physician Attendance (3.00 hours)

You are not logged in.

Please click the button below to login or create a new account before continuing.

Mitigation of Relevant Financial Relationships

The Accreditation Council for Continuing Medical Education (ACCME), Standards for Integrity and Independence mandates that the accreditation manages all identified relevant financial relationship(s) before the program and adequately discloses relationships to learners. The David Geffen School of Medicine at UCLA adheres to the ACCME Standards for Integrity and Independence in accredited continuing education.

The individuals below have been identified as having a position to influence the content of this educational activity. As such, they have disclosed the absence or presence of a relevant financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All of the relevant financial relationships for these individuals have been mitigated.

Thursday, January 23, 2025